Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHA:603811)

Market Cap	3.14B -19.2%
Revenue (ttm)	827.75M +10.8%
Net Income	193.61M -9.4%
EPS	0.44 -6.1%
Shares Out	444.76M
PE Ratio	16.17
Forward PE	n/a
Dividend	0.21 (3.01%)
Ex-Dividend Date	Jun 26, 2026

Volume	3,331,060
Open	7.09
Previous Close	7.13
Day's Range	7.01 - 7.18
52-Week Range	6.83 - 12.12
Beta	0.12
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About SHA:603811

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. engages in the research, development, production, and sales of formulations and active pharmaceutical ingredients in China and internationally. The company offers glucosamine hydrochloride raw materials and preparations, gastrodin raw materials, ribavirin preparations raw materials, and sulfur dioxide raw materials. It also provides injections, food, capsules, tablets, traditional Chinese medicines, preparations, and intermediates; and joint-related drugs, diuretics and antihypertensive drugs, antivira...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1966
• Employees: 604
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603811

Financial Performance

In 2025, SHA:603811's revenue was 812.35 million, an increase of 13.72% compared to the previous year's 714.37 million. Earnings were 195.12 million, a decrease of -2.78%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 30, 2026

Data Sources Report a data error